K

D

Digitalis Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

7

Common Fundraising Type

Series B

G
Galatea Bio

AI-driven • Genomic research

Stanford logo
Helios Digital Ventures logo
HBM Genomics logo
Founders Collective logo

Galatea Bio is a biotechnology company that uses AI-driven genomic research and clinical genetic testing to advance precision medicine and improve genetic risk analysis, biomarker discovery, and clinical trials optimization.

Equity
$25M
03/27/2025
Article
N
Napo

Pet insurance • AI

Mercia Ventures logo
MTech Capital logo
Helvetia logo
DN Capital logo

Napo is a pet insurance startup that uses AI-driven claims handling to offer comprehensive coverage, including dental and behavioral treatments, with a focus on sustainability and quality.

Series B
$15.2M
02/26/2025
Article
Aviceda Therapeutics logo
Aviceda Therapeutics

Biotech • Immunomodulators

TCGX logo
Omega Funds logo
Jeito Capital logo
Enavate Sciences logo

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Series C
$207.5M
01/07/2025
Article
Nuvig Therapeutics logo
Nuvig Therapeutics

Biotechnology • Autoimmune Diseases

Sanofi Ventures logo
Blue Owl Healthcare Opportunities logo
Norwest Venture Partners logo
Novo Holdings logo

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Series B
$161M
12/05/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals • Clinical-stage

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
Terray Therapeutics logo
Terray Therapeutics

Biotechnology • Small Molecule Drug Discovery

XTX Ventures logo
Two Sigma Ventures logo
NVentures logo
Maverick Capital logo

Terray Therapeutics integrates ultra-high throughput experimentation with generative AI, biology, medicinal chemistry, automation, and nanotechnology to transform small molecule drug discovery.

Series B
$120M
10/17/2024
Article
T-Therapeutics logo
T-Therapeutics

Biotech • TCR Therapeutics

Sofinnova Partners logo
University of Cambridge logo
Sanofi Ventures logo
F-Prime Capital logo

T-Therapeutics is a biotech firm specializing in developing TCR therapeutics for cancer and inflammatory disorders using their proprietary OpTiMus® platform.

Series A
$59.6M
11/16/2023
Article